Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.

Larson CA, Adams PL, Blair BG, Safaei R, Howell SB.

Mol Pharmacol. 2010 Sep;78(3):333-9. doi: 10.1124/mol.110.064766. Epub 2010 Jun 2.

2.

The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin.

Larson CA, Adams PL, Jandial DD, Blair BG, Safaei R, Howell SB.

Biochem Pharmacol. 2010 Aug 15;80(4):448-54. doi: 10.1016/j.bcp.2010.04.030. Epub 2010 May 6. Erratum in: Biochem Pharmacol. 2010 Dec 1;80(11):1768.

3.

Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.

Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT.

Mol Cancer Ther. 2004 Dec;3(12):1543-9. Erratum in: Mol Cancer Ther. 2005 May;4(5):864.

4.

A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.

Ivy KD, Kaplan JH.

Mol Pharmacol. 2013 Jun;83(6):1237-46. doi: 10.1124/mol.113.085068. Epub 2013 Mar 29.

5.

Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1).

Du X, Wang X, Li H, Sun H.

Metallomics. 2012 Jul;4(7):679-85. doi: 10.1039/c2mt20021j. Epub 2012 May 3.

PMID:
22552365
6.

The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, Howell SB.

Mol Pharmacol. 2004 Oct;66(4):817-23. Epub 2004 Jun 30.

7.
8.

Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.

Tsai CY, Larson CA, Safaei R, Howell SB.

Biochem Pharmacol. 2014 Aug 15;90(4):379-87. doi: 10.1016/j.bcp.2014.06.019. Epub 2014 Jun 23.

9.

Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1.

Wu Z, Liu Q, Liang X, Yang X, Wang N, Wang X, Sun H, Lu Y, Guo Z.

J Biol Inorg Chem. 2009 Nov;14(8):1313-23. doi: 10.1007/s00775-009-0576-7. Epub 2009 Aug 8.

PMID:
19669174
10.

Overcoming platinum drug resistance with copper-lowering agents.

Chen HH, Kuo MT.

Anticancer Res. 2013 Oct;33(10):4157-61. Review.

11.

The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.

Lin X, Okuda T, Holzer A, Howell SB.

Mol Pharmacol. 2002 Nov;62(5):1154-9. Erratum in: Mol Pharmacol. 2003 Apr;63(4):957.

12.

Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.

Howell SB, Safaei R, Larson CA, Sailor MJ.

Mol Pharmacol. 2010 Jun;77(6):887-94. doi: 10.1124/mol.109.063172. Epub 2010 Feb 16. Review.

13.

Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin.

Liang ZD, Stockton D, Savaraj N, Tien Kuo M.

Mol Pharmacol. 2009 Oct;76(4):843-53. doi: 10.1124/mol.109.056416. Epub 2009 Jul 1.

14.

Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.

Shang X, Lin X, Manorek G, Howell SB.

Mol Pharmacol. 2013 Jan;83(1):85-94. doi: 10.1124/mol.112.079798. Epub 2012 Oct 10.

15.

Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1.

Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, Lu J, Wu LY, Siddik ZH, Klomp LW, Savaraj N, Kuo MT.

Mol Pharmacol. 2008 Sep;74(3):697-704. doi: 10.1124/mol.108.047969. Epub 2008 Jun 3.

16.

Mechanistic basis for overcoming platinum resistance using copper chelating agents.

Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT.

Mol Cancer Ther. 2012 Nov;11(11):2483-94. doi: 10.1158/1535-7163.MCT-12-0580. Epub 2012 Aug 21.

17.

Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin.

Matsumoto S, Tanaka T, Kurokawa H, Matsuno K, Hayashida Y, Takahashi T.

Anticancer Res. 2007 Jul-Aug;27(4B):2209-16.

18.
19.

Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.

Liang ZD, Long Y, Chen HH, Savaraj N, Kuo MT.

J Biol Inorg Chem. 2014 Jan;19(1):17-27. doi: 10.1007/s00775-013-1051-z. Epub 2013 Oct 17.

20.

Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.

Safaei R, Maktabi MH, Blair BG, Larson CA, Howell SB.

J Inorg Biochem. 2009 Mar;103(3):333-41. doi: 10.1016/j.jinorgbio.2008.11.012. Epub 2008 Nov 30.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk